Bitcoin groundbreakers share personal stories of how Bitcoin is changing lives for the better. Host Mauricio Di Bartolomeo, co-founder and CSO of Ledn, speaks with leading Bitcoin voices, entrepreneurs, and human rights advocates to hear their unique journey and practical real-world examples of how Bitcoin has made a positive impact in their lives. Brought to you by Ledn, a leading financial services company built for Bitcoin & digital assets. Ledn offers a suite of lending, saving and tradi ...
…
continue reading
Innehåll tillhandahållet av Proactive Investors. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Proactive Investors eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !
Gå offline med appen Player FM !
Tryptamine Therapeutics completes phase 1b of IV-infused psilocin trial
MP3•Episod hem
Manage episode 436376774 series 2891889
Innehåll tillhandahållet av Proactive Investors. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Proactive Investors eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
Tryptamine Therapeutics Ltd (ASX:TYP, OTC:TYPTF) CEO Jason Carroll joins Proactive’s Tylah Tully to discuss the completion of dosing all participants in its Phase 1b IV-infused psilocin Healthy Human Volunteer Study conducted at CMAX Clinical Research in Adelaide. This trial involved the administration of TRP-8803, a proprietary IV-infused psilocin formulation, to 11 participants across three cohorts over a period of up to 150 minutes. The study aimed to refine dosing and infusion rates to maintain precise blood levels of psilocin for optimal therapeutic effects. All participants were safely discharged following treatment and dosing follow-up. This Phase 1b trial provided key insights into the blood concentration limits of psilocin required to maintain an ideal therapeutic zone. The results will support future patent applications and underpin upcoming trials targeting binge eating disorder (BED) and fibromyalgia syndrome (FMS). Carroll highlighted the trial's significance in advancing the company’s proprietary IV-infusion technology, which may overcome challenges associated with oral dosing of psychedelics. A Safety Review Council is evaluating the trial data to determine if safety criteria was met. The company will provide further updates upon review completion. Successful Phase 2a trials with TRP-8802 (oral psilocybin) have de-risked upcoming TRP-8803 trials. #Proactiveinvestors #TryptamineTherapeutics #ASX #Psilocin #ClinicalTrial #Phase1b #IVInfusion #Psychedelics #TRP8803 #TRP8802 #BingeEatingDisorder #Fibromyalgia #ClinicalResearch #CMAX #Adelaide #TherapeuticGoodsAdministration #Pharmaceutical #MentalHealth #SafetyReview #PatentApplication #DrugDevelopment #PatientSafety #Therapeutics #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
608 episoder
MP3•Episod hem
Manage episode 436376774 series 2891889
Innehåll tillhandahållet av Proactive Investors. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Proactive Investors eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
Tryptamine Therapeutics Ltd (ASX:TYP, OTC:TYPTF) CEO Jason Carroll joins Proactive’s Tylah Tully to discuss the completion of dosing all participants in its Phase 1b IV-infused psilocin Healthy Human Volunteer Study conducted at CMAX Clinical Research in Adelaide. This trial involved the administration of TRP-8803, a proprietary IV-infused psilocin formulation, to 11 participants across three cohorts over a period of up to 150 minutes. The study aimed to refine dosing and infusion rates to maintain precise blood levels of psilocin for optimal therapeutic effects. All participants were safely discharged following treatment and dosing follow-up. This Phase 1b trial provided key insights into the blood concentration limits of psilocin required to maintain an ideal therapeutic zone. The results will support future patent applications and underpin upcoming trials targeting binge eating disorder (BED) and fibromyalgia syndrome (FMS). Carroll highlighted the trial's significance in advancing the company’s proprietary IV-infusion technology, which may overcome challenges associated with oral dosing of psychedelics. A Safety Review Council is evaluating the trial data to determine if safety criteria was met. The company will provide further updates upon review completion. Successful Phase 2a trials with TRP-8802 (oral psilocybin) have de-risked upcoming TRP-8803 trials. #Proactiveinvestors #TryptamineTherapeutics #ASX #Psilocin #ClinicalTrial #Phase1b #IVInfusion #Psychedelics #TRP8803 #TRP8802 #BingeEatingDisorder #Fibromyalgia #ClinicalResearch #CMAX #Adelaide #TherapeuticGoodsAdministration #Pharmaceutical #MentalHealth #SafetyReview #PatentApplication #DrugDevelopment #PatientSafety #Therapeutics #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
608 episoder
همه قسمت ها
×Välkommen till Player FM
Player FM scannar webben för högkvalitativa podcasts för dig att njuta av nu direkt. Den är den bästa podcast-appen och den fungerar med Android, Iphone och webben. Bli medlem för att synka prenumerationer mellan enheter.